These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26713614)

  • 1. Pregnancy Outcomes after a Mass Vaccination Campaign with an Oral Cholera Vaccine in Guinea: A Retrospective Cohort Study.
    Grout L; Martinez-Pino I; Ciglenecki I; Keita S; Diallo AA; Traore B; Delamou D; Toure O; Nicholas S; Rusch B; Staderini N; Serafini M; Grais RF; Luquero FJ
    PLoS Negl Trop Dis; 2015 Dec; 9(12):e0004274. PubMed ID: 26713614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study.
    Ali M; Nelson A; Luquero FJ; Azman AS; Debes AK; M'bang'ombe MM; Seyama L; Kachale E; Zuze K; Malichi D; Zulu F; Msyamboza KP; Kabuluzi S; Sack DA
    Lancet Infect Dis; 2017 May; 17(5):538-544. PubMed ID: 28161570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of a bivalent, killed, whole-cell oral cholera vaccine in pregnant women in Bangladesh: evidence from a randomized placebo-controlled trial.
    Khan AI; Ali M; Lynch J; Kabir A; Excler JL; Khan MA; Islam MT; Akter A; Chowdhury F; Saha A; Khan IA; Desai SN; Kim DR; Saha NC; Singh AP; Clemens JD; Qadri F
    BMC Infect Dis; 2019 May; 19(1):422. PubMed ID: 31092224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh.
    Khan AI; Ali M; Chowdhury F; Saha A; Khan IA; Khan A; Akter A; Asaduzzaman M; Islam MT; Kabir A; You YA; Saha NC; Cravioto A; Clemens JD; Qadri F
    Vaccine; 2017 Mar; 35(11):1538-1543. PubMed ID: 28196715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First outbreak response using an oral cholera vaccine in Africa: vaccine coverage, acceptability and surveillance of adverse events, Guinea, 2012.
    Luquero FJ; Grout L; Ciglenecki I; Sakoba K; Traore B; Heile M; Dialo AA; Itama C; Serafini M; Legros D; Grais RF
    PLoS Negl Trop Dis; 2013; 7(10):e2465. PubMed ID: 24147164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine: a systematic review and meta-analysis.
    Zhang Y; Zhang H; Wang B; Song G; Hayden JC; Amirthalingam P; Rahmani J; Bhagavathula AS; Li Z
    BJOG; 2020 Aug; 127(9):1066-1073. PubMed ID: 32289871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effectiveness of one and two doses of a killed, bivalent, whole-cell oral cholera vaccine in Haiti: an extended case-control study.
    Franke MF; Ternier R; Jerome JG; Matias WR; Harris JB; Ivers LC
    Lancet Glob Health; 2018 Sep; 6(9):e1028-e1035. PubMed ID: 30103980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass vaccination with a new, less expensive oral cholera vaccine using public health infrastructure in India: the Odisha model.
    Kar SK; Sah B; Patnaik B; Kim YH; Kerketta AS; Shin S; Rath SB; Ali M; Mogasale V; Khuntia HK; Bhattachan A; You YA; Puri MK; Lopez AL; Maskery B; Nair GB; Clemens JD; Wierzba TF
    PLoS Negl Trop Dis; 2014 Feb; 8(2):e2629. PubMed ID: 24516675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral cholera vaccine coverage during a preventive door-to-door mass vaccination campaign in Nampula, Mozambique.
    Semá Baltazar C; Rafael F; Langa JPM; Chicumbe S; Cavailler P; Gessner BD; Pezzoli L; Barata A; Zaina D; Inguane DL; Mengel MA; Munier A
    PLoS One; 2018; 13(10):e0198592. PubMed ID: 30281604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs of illness due to cholera, costs of immunization and cost-effectiveness of an oral cholera mass vaccination campaign in Zanzibar.
    Schaetti C; Weiss MG; Ali SM; Chaignat CL; Khatib AM; Reyburn R; Duintjer Tebbens RJ; Hutubessy R
    PLoS Negl Trop Dis; 2012; 6(10):e1844. PubMed ID: 23056660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and acceptability of oral cholera vaccine mass vaccination campaign in response to an outbreak and floods in Malawi.
    Msyamboza KP; M'bang'ombe M; Hausi H; Chijuwa A; Nkukumila V; Kubwalo HW; Desai S; Pezzoli L; Legros D
    Pan Afr Med J; 2016; 23():203. PubMed ID: 27347292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of a cholera rapid diagnostic test during a mass vaccination campaign in response to an epidemic in Guinea, 2012.
    Martinez-Pino I; Luquero FJ; Sakoba K; Sylla S; Haile M; Grais RF; Ciglenecki I; Quilici ML; Page AL
    PLoS Negl Trop Dis; 2013; 7(8):e2366. PubMed ID: 23967359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A reactive vaccination campaign with single dose oral cholera vaccine (OCV) during a cholera outbreak in Cameroon.
    Amani A; Tatang CA; Bayiha CN; Woung M; Ngo Bama S; Nangmo A; Mbang MA; Epee Douba E
    Vaccine; 2021 Feb; 39(8):1290-1296. PubMed ID: 33494966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral cholera vaccination coverage after the first global stockpile deployment in Haiti, 2014.
    Burnett EM; Francois J; Sreenivasan N; Wannemuehler K; Faye PC; Tohme RA; Delly P; Deslouches YG; Etheart MD; Dismer AM; Patel R; Date K
    Vaccine; 2019 Oct; 37(43):6348-6355. PubMed ID: 31521413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mass vaccination with a two-dose oral cholera vaccine in a long-standing refugee camp, Thailand.
    Phares CR; Date K; Travers P; Déglise C; Wongjindanon N; Ortega L; Bhuket PR
    Vaccine; 2016 Jan; 34(1):128-33. PubMed ID: 26549363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Secreting Cell Responses following Vaccination with Bivalent Oral Cholera Vaccine among Haitian Adults.
    Matias WR; Falkard B; Charles RC; Mayo-Smith LM; Teng JE; Xu P; Kováč P; Ryan ET; Qadri F; Franke MF; Ivers LC; Harris JB
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004753. PubMed ID: 27308825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of a One-Dose versus Two-Dose Oral Cholera Vaccine Regimen in Outbreak Settings: A Modeling Study.
    Azman AS; Luquero FJ; Ciglenecki I; Grais RF; Sack DA; Lessler J
    PLoS Med; 2015 Aug; 12(8):e1001867. PubMed ID: 26305226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neighborhood-targeted and case-triggered use of a single dose of oral cholera vaccine in an urban setting: Feasibility and vaccine coverage.
    Parker LA; Rumunu J; Jamet C; Kenyi Y; Lino RL; Wamala JF; Mpairwe AM; Muller V; Llosa AE; Uzzeni F; Luquero FJ; Ciglenecki I; Azman AS
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005652. PubMed ID: 28594891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Delayed second dose of oral cholera vaccine administered before high-risk period for cholera transmission: Cholera control strategy in Lusaka, 2016.
    Ferreras E; Matapo B; Chizema-Kawesha E; Chewe O; Mzyece H; Blake A; Moonde L; Zulu G; Poncin M; Sinyange N; Kasese-Chanda N; Phiri C; Malama K; Mukonka V; Cohuet S; Uzzeni F; Ciglenecki I; Danovaro-Holliday MC; Luquero FJ; Pezzoli L
    PLoS One; 2019; 14(8):e0219040. PubMed ID: 31469853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral cholera vaccination coverage in an acute emergency setting in Somalia, 2017.
    Lubogo M; Mohamed AM; Ali AH; Ali AH; Popal GR; Kiongo D; Bile KM; Malik M; Abubakar A
    Vaccine; 2020 Feb; 38 Suppl 1():A141-A147. PubMed ID: 31980193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.